🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Hangzhou Dinova EP Technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Hangzhou Dinova EP Technology as lead sponsor. Synced 26 Sep 2026
4Current trials
2Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Hangzhou Dinova EP Technology is the lead sponsor of 4 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Not applicable. The most-studied condition is Atrial Fibrillation (AF).

ClinicalTrials.gov trials by status

  • Recruiting250%
  • Not yet open250%

Trials by phase

  • Not applicable4100%
01

Clinical trials sponsored by Hangzhou Dinova EP Technology

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Comparison of Different Pulsed Field Ablation Catheters in Atrial Fibrillation
NCT07036965 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF)
Not applicable Recruiting 2025-06 China
An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia
NCT06157437 · ClinicalTrials.gov ↗ · Typical Atrial Flutter, Atrial Fibrillation (AF)
Not applicable Recruiting 2023-12 China
Study on the Safety and Effectiveness of the SnowyTM PFO Closure System
NCT05360771 · ClinicalTrials.gov ↗ · Patent Foramen Ovale
Not applicable Not yet open 2023-10 China
A Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.
NCT07590661 · ClinicalTrials.gov ↗ · Persistent Atrial Fibrillation
Not applicable Not yet open 2026-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Hangzhou Dinova EP Technology trials

4 conditions
Atrial Fibrillation (AF)2Patent Foramen Ovale1Typical Atrial Flutter1Persistent Atrial Fibrillation1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China42

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Atrial Fibrillation (AF)

SponsorTrials
Beijing Anzhen Hospital13
Shanghai Chest Hospital6
Second Affiliated Hospital of Nanchang University2
Jiangsu Taizhou People's Hospital2
Lanzhou University Second Hospital1

Sponsors with the most current trials registered for this condition.

05

Questions about Hangzhou Dinova EP Technology trials

How many clinical trials does Hangzhou Dinova EP Technology sponsor?

Hangzhou Dinova EP Technology is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hangzhou Dinova EP Technology trials recruiting?

Yes. 2 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.